
very low)

2.1.2.

For patients with symptomatic varicose veins and axial reﬂux in the GSV or SSV who are
candidates for intervention, we recommend superﬁcial venous intervention over longterm compression stockings.

1 (strong)

B
(moderate)

2.1.3.

For patients with symptomatic varicose veins and axial reﬂux in the AAGSV or PAGSV, who 2 (weak)
are candidates for intervention, we suggest superﬁcial venous intervention over long-term
compression stockings.

C (low to
very low)

2.1.4.

In patients with symptomatic varicose veins who are candidates for endovenous therapy
and wish to proceed with treatment, we suggest against a 3-month trial of compression
therapy before intervention.

2 (weak)

B
(moderate)

2 (weak)

B
(moderate)

Guidelines

Grade of
recommendation

Quality of
Evidence

3.1.

In symptomatic patients with varicose veins who are not candidates for intervention, or
who are waiting for intervention or have symptoms after intervention, we suggest
micronized puriﬁed ﬂavonoid fraction or Ruscus extracts for treatment of vein related pain,
leg heaviness and/or sensation of swelling. a

2 (weak)

B
(moderate)

3.2.

In symptomatic patients with varicose veins who are not candidates for intervention, or
2 (weak)
who are waiting for intervention or have symptoms after intervention, we suggest
hydroxyethylrutosides, calcium dobesilate, horse chestnut extract, red vine leaf extract, or
sulodexide for treatment of vein-related pain, leg heaviness, night cramps and/or sensation
of swelling.a

2.2 Compression therapy after intervention
2.2.1.

In patients undergoing thermal ablation for saphenous incompetence, with or without
concomitant phlebectomy, we suggest postprocedure compression therapy for a
minimum of 1 week for pain reduction.
3. Pharmacological treatment

a

C (low to
very low)

These products are not approved drugs by the U.S. Food and Drug Administration (FDA). The FDA does not approve medical food
or nutritional supplements (https://www.fda.gov/).
4.1. Endovenous ablation